Novavax, Inc. (NVAX) Release: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus (MERS-Cov)
4/30/2014 9:57:20 AM
BALTIMORE and GAITHERSBURG, Md., April 30, 2014 (GLOBE NEWSWIRE) -- The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. (Nasdaq:NVAX) today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus (MERS-CoV) blocked infection in laboratory studies. UM SOM and Novavax also reported that a vaccine candidate against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) developed by Novavax on a similar platform also inhibited virus infection. Researchers reported these findings in an article published in the April 13, 2014 issue of Vaccine1.
Help employers find you! Check out all the jobs and post your resume.
comments powered by